<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="244">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00986102</url>
  </required_header>
  <id_info>
    <org_study_id>CR016321</org_study_id>
    <secondary_id>DORIBAC4007</secondary_id>
    <nct_id>NCT00986102</nct_id>
  </id_info>
  <brief_title>PROUD Study: A Prospective Study on the Usage Patterns of Doripenem in the Asia Pacific Region</brief_title>
  <official_title>A Prospective Study on the Usage Patterns of Doripenem in the Asia Pacific Region</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johnson &amp; Johnson Pte Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Johnson &amp; Johnson (Hong Kong) Ltd.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Johnson &amp; Johnson Pte Ltd</source>
  <oversight_info>
    <authority>Singapore: Health Sciences Authority</authority>
    <authority>Vietnam: Ministry of Health</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to understand the utilization patterns of doripenem in Asia
      Pacific, including the profile of the patients treated with carbapenems.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 4, prospective, open-label, non-comparative, multicenter study to
      characterize the usage of doripenem in selected hospitals in the Asia Pacific region.
      Doripenem belongs to the carbapenem class which is a broad-spectrum antibiotic given to
      treat patients with serious infections, such as pneumonia and complicated intra-abdominal
      infections. Physicians in the selected hospital or hospital unit will refer potential
      patients to the study team. Patients will include men and women 18 years of age and older,
      hospitalized either in the Intensive Care Unit (ICU) or ward, with a diagnosis of pneumonia,
      complicated intra-abdominal infections and complicated urinary tract infections. The study
      has 3 phases: a pretreatment phase with a 1-day screening/baseline visit, a treatment phase
      of 5 to 14 days, and a post-treatment phase consisting of an end-of-treatment (EOT)/early
      withdrawal visit to be conducted within 24 hours after the last dose of antimicrobial
      therapy, a test of cure (TOC) visit 7 to 14 days after EOT, a Day 28 visit, and a
      post-discharge visit 28 days after discharge from the hospital. Usage of Doripenem in terms
      of approved indications, mode of usage, duration of antibiotic therapy, and patient
      characteristics will be assessed. Safety will be assessed through monitoring for adverse
      events, serial physical examinations, and the collection of conventional laboratory data
      (chemistry panel, complete blood count with differential). Being a prospective study,
      patient data will be gathered as the patients are enrolled, starting with their present
      condition and following them until duration of the study. The study will not compare
      Doripenem with other antibiotics for the primary endpoint. One vial (500mg) of doripenem
      intravenously (by injection) every 8 hours for 5 to 14 days
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2009</start_date>
  <completion_date type="Actual">September 2011</completion_date>
  <primary_completion_date type="Actual">September 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Number of Participants With the Usage of Doripenem as Per the Approved Indication</measure>
    <time_frame>5 to 14 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Early onset of Nosocomial Pneumonia (NP) and Ventilator-Associated Pneumonia (VAP) is defined as less than 5 days after hospitalization and late onset of NP and VAP is defined as more than or equal to 5 days after hospitalization</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Different Mode of Usage of Doripenem</measure>
    <time_frame>5 to 14 days</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Duration of Antibiotic Therapy</measure>
    <time_frame>5 to 14 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Duration of doripenem and duration of doripenem plus oral antibiotics therapy</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Acute Physiology and Chronic Health Evaluation II (APACHE II) Score</measure>
    <time_frame>Baseline (Day -1)</time_frame>
    <safety_issue>No</safety_issue>
    <description>APACHE II is a severity of disease classification system and the score will be determined in the participants admitted to the Intensive Care Unit upon study enrollment to help predict the risk of mortality for critically ill patients. It consists of, A: acute physiology score (APS; range, 0 to 4), B: age points (range, 0 [less than or equal to 44] to 6 [greater than or equal to 75]) and C: chronic health points (2 [elective postoperative patient] and 5 [non-operative or emergency postoperative patient]). Total APACHE II score is sum of A, B and C.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Achieved Clinical Cure, Clinical Failure and Intermediate Outcome at End-of-treatment Visit (EOT)</measure>
    <time_frame>Day 5 or Day 7 or Day 14</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Achieved Clinical Cure, or Experienced Clinical Failure, Relapse or Intermediate Outcome at Test-of-cure (TOC) Visit</measure>
    <time_frame>End-of-treatment (Day 5 or Day 7 or Day 14) plus 7 to 14 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Experienced Eradication, Presumed Eradication, Persistence, Presumed Persistence and Indeterminate Response at End-of-treatment Visit (EOT) Visit</measure>
    <time_frame>Day 5 or Day 7 or Day 14</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Medical Resource Utilization</measure>
    <time_frame>From Baseline (Day -1) upto the duration of hospital stay of a participant</time_frame>
    <safety_issue>No</safety_issue>
    <description>Medical resource utilization included length of hospital stay, length of intensive care unit (ICU) stay, duration of mechanical ventilation and time to discharge.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Readmitted to the Intensive Care Unit (ICU) Within 28 Days After End-of-treatment (EOT)</measure>
    <time_frame>Within 28 days after EOT (Day 5 or Day 7 or Day 14)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Readmitted to the Hospital Within 28 Days After End-of-treatment (EOT)</measure>
    <time_frame>Within 28 days after EOT (Day 5 or Day 7 or Day 14)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">216</enrollment>
  <condition>Pneumonia</condition>
  <condition>Pneumonia, Ventilator-Associated</condition>
  <condition>Urinary Tract Infections</condition>
  <arm_group>
    <arm_group_label>001</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>doripenem 500mg vial by injection every 8 hours for 5 to 14 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>doripenem</intervention_name>
    <description>500mg vial by injection every 8 hours for 5 to 14 days</description>
    <arm_group_label>001</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients hospitalized either in the ICU or ward, with a diagnosis of pneumonia,
             complicated abdominal infections, or complicated urinary tract infection using the
             protocol-defined Guidelines for Diagnosis

        Exclusion Criteria:

          -  Pregnant or lactating females

          -  Allergies to Doripenem or its derivatives

          -  Infected by a bacteria that is resistant to Doripenem

          -  Taking probenecid

          -  Severe allergies to other antibiotics like penicillins, cephalosporins, or
             carbapenems

          -  Severe kidney disease, in an unstable disease state and assessed as unlikely to
             survive until the study follow up period

          -  Signs of severe sepsis with treatment failure with other carbapenems, who received
             other carbapenem within 2 weeks before first dose of study drug, and who has any
             condition that, in the opinion of the investigator, would compromise the well-being
             of the patient or the study or prevent the patient from meeting or performing study
             requirements
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Johnson &amp; Johnson Pte. Ltd. Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Johnson &amp; Johnson Pte Ltd</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Hk</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bandung</city>
        <country>Indonesia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jakarta</city>
        <country>Indonesia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Surabaya</city>
        <country>Indonesia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ipoh</city>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Johor Bahru</city>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kota Bharu</city>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kuala Lumpur K Lumpur</city>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kuala Lumpur N/A</city>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pulau Pinang</city>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Selangor</city>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seremban</city>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Terengganu</city>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Singapore</city>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hanoi</city>
        <country>Vietnam</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ho Chi Minh City</city>
        <country>Vietnam</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Hong Kong</country>
    <country>Indonesia</country>
    <country>Malaysia</country>
    <country>Singapore</country>
    <country>Vietnam</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <lastchanged_date>January 4, 2013</lastchanged_date>
  <firstreceived_date>September 25, 2009</firstreceived_date>
  <firstreceived_results_date>January 4, 2013</firstreceived_results_date>
  <responsible_party>
    <name_title>Therapeutic Area Physician, Anti-Infectives</name_title>
    <organization>Johnson &amp; Johnson (Philippines) Inc., Philippines</organization>
  </responsible_party>
  <keyword>Carbapenem</keyword>
  <keyword>Doripenem</keyword>
  <keyword>Doribax</keyword>
  <keyword>Nosocomial pneumonia, Intra-abdominal infections</keyword>
  <keyword>Urinary tract infection</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>Pneumonia, Ventilator-Associated</mesh_term>
    <mesh_term>Urinary Tract Infections</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>217 patients were enrolled at sites in Malaysia, Indonesia, Singapore, Vietnam and Hong Kong.</recruitment_details>
      <pre_assignment_details>217 patients were enrolled and 216 received study medication. 1 patient was enrolled but subsequently withdrew consent before receiving the study medication. 61 patients discontinued study medication prior to end of treatment.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Nosocomial Pneumonia (NP)</title>
          <description>500 mg of doripenem was administered every 8 hours as 1 or 4-hour infusion for 7 to 14 days</description>
        </group>
        <group group_id="P2">
          <title>Ventilator-Associated Pneumonia (VAP)</title>
          <description>500 mg of doripenem was administered every 8 hours as 1 or 4-hour infusion for 7 to 14 days</description>
        </group>
        <group group_id="P3">
          <title>Complicated Urinary Tract Infection (cUTI)</title>
          <description>500 mg of doripenem was administered every 8 hours as 1-hour infusion for 5 to 14 days</description>
        </group>
        <group group_id="P4">
          <title>Complicated Intra-abdominal Infection (cIAI)</title>
          <description>500 mg of doripenem was administered every 8 hours as 1-hour infusion for 10 days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="53">Number of participants who received study medication</participants>
                <participants group_id="P2" count="77">Number of participants who received study medication</participants>
                <participants group_id="P3" count="19">Number of participants who received study medication</participants>
                <participants group_id="P4" count="67">Number of participants who received study medication</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="52"/>
                <participants group_id="P2" count="75"/>
                <participants group_id="P3" count="19"/>
                <participants group_id="P4" count="66"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Nosocomial Pneumonia (NP)</title>
          <description>500 mg of doripenem was administered every 8 hours as 1 or 4-hour infusion for 7 to 14 days</description>
        </group>
        <group group_id="B2">
          <title>Ventilator-Associated Pneumonia (VAP)</title>
          <description>500 mg of doripenem was administered every 8 hours as 1 or 4-hour infusion for 7 to 14 days</description>
        </group>
        <group group_id="B3">
          <title>Complicated Urinary Tract Infection (cUTI)</title>
          <description>500 mg of doripenem was administered every 8 hours as 1-hour infusion for 5 to 14 days</description>
        </group>
        <group group_id="B4">
          <title>Complicated Intra-abdominal Infection (cIAI)</title>
          <description>500 mg of doripenem was administered every 8 hours as 1-hour infusion for 10 days</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="53"/>
                <measurement group_id="B2" value="77"/>
                <measurement group_id="B3" value="19"/>
                <measurement group_id="B4" value="67"/>
                <measurement group_id="B5" value="216"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="54.1" spread="17.52"/>
                <measurement group_id="B2" value="44.4" spread="19.17"/>
                <measurement group_id="B3" value="58.2" spread="13.23"/>
                <measurement group_id="B4" value="49.2" spread="16.13"/>
                <measurement group_id="B5" value="49.5" spread="17.88"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="16"/>
                <measurement group_id="B2" value="19"/>
                <measurement group_id="B3" value="13"/>
                <measurement group_id="B4" value="24"/>
                <measurement group_id="B5" value="72"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="37"/>
                <measurement group_id="B2" value="58"/>
                <measurement group_id="B3" value="6"/>
                <measurement group_id="B4" value="43"/>
                <measurement group_id="B5" value="144"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Chinese</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="8"/>
                <measurement group_id="B2" value="13"/>
                <measurement group_id="B3" value="7"/>
                <measurement group_id="B4" value="28"/>
                <measurement group_id="B5" value="56"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Malay</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="33"/>
                <measurement group_id="B2" value="44"/>
                <measurement group_id="B3" value="8"/>
                <measurement group_id="B4" value="35"/>
                <measurement group_id="B5" value="120"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Indian</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="2"/>
                <measurement group_id="B2" value="3"/>
                <measurement group_id="B3" value="2"/>
                <measurement group_id="B4" value="0"/>
                <measurement group_id="B5" value="7"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Aboriginal</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
                <measurement group_id="B4" value="1"/>
                <measurement group_id="B5" value="1"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>White</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="1"/>
                <measurement group_id="B3" value="0"/>
                <measurement group_id="B4" value="1"/>
                <measurement group_id="B5" value="2"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Others</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="10"/>
                <measurement group_id="B2" value="16"/>
                <measurement group_id="B3" value="2"/>
                <measurement group_id="B4" value="2"/>
                <measurement group_id="B5" value="30"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Patient's location in the hospital upon enrollment</title>
          <units>Participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Intensive Care Unit (ICU)</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="30"/>
                <measurement group_id="B2" value="69"/>
                <measurement group_id="B3" value="9"/>
                <measurement group_id="B4" value="29"/>
                <measurement group_id="B5" value="137"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Non â€“ICU</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="23"/>
                <measurement group_id="B2" value="8"/>
                <measurement group_id="B3" value="10"/>
                <measurement group_id="B4" value="36"/>
                <measurement group_id="B5" value="77"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Missing</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
                <measurement group_id="B4" value="2"/>
                <measurement group_id="B5" value="2"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With the Usage of Doripenem as Per the Approved Indication</title>
        <description>Early onset of Nosocomial Pneumonia (NP) and Ventilator-Associated Pneumonia (VAP) is defined as less than 5 days after hospitalization and late onset of NP and VAP is defined as more than or equal to 5 days after hospitalization</description>
        <time_frame>5 to 14 days</time_frame>
        <safety_issue>No</safety_issue>
        <population>Intent-to-treat (ITT) population: Included all enrolled participants who received at least one dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Nosocomial Pneumonia (NP)</title>
            <description>500 mg of doripenem was administered every 8 hours as 1 or 4-hour infusion for 7 to 14 days</description>
          </group>
          <group group_id="O2">
            <title>Ventilator-Associated Pneumonia (VAP)</title>
            <description>500 mg of doripenem was administered every 8 hours as 1 or 4-hour infusion for 7 to 14 days</description>
          </group>
          <group group_id="O3">
            <title>Complicated Urinary Tract Infection (cUTI)</title>
            <description>500 mg of doripenem was administered every 8 hours as 1-hour infusion for 5 to 14 days</description>
          </group>
          <group group_id="O4">
            <title>Complicated Intra-abdominal Infection (cIAI)</title>
            <description>500 mg of doripenem was administered every 8 hours as 1-hour infusion for 10 days</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="53"/>
                  <measurement group_id="O2" value="77"/>
                  <measurement group_id="O3" value="19"/>
                  <measurement group_id="O4" value="67"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Participants With the Usage of Doripenem as Per the Approved Indication</title>
            <description>Early onset of Nosocomial Pneumonia (NP) and Ventilator-Associated Pneumonia (VAP) is defined as less than 5 days after hospitalization and late onset of NP and VAP is defined as more than or equal to 5 days after hospitalization</description>
            <units>Participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Early onset of NP</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="23"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Late onset of NP</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="30"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Early onset of VAP</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="32"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Late onset of VAP</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="45"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Acute Pyelonephritis</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="11"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Emphysematous Pyelonephritis</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="1"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Prostate Infection</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="1"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Pyelonephritis</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="1"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Pyonephrosis</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="1"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urosepsis</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="2"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Complicated lower urinary tract infection</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="2"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Abdominal Abscess</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Appendiceal Abscess</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Appendicitis</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Appendicitis Perforated</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="24"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Cholecystitis Acute</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Diverticular Perforation</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Duodenal Ulcer Perforation</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Gallbladder Empyema</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Gastric Perforation</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Gastric Ulcer Perforation</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Gastrointestinal Anastomotic Leak</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Gastrointestinal Stoma Complication</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Ileal Perforation</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Intestinal Perforation</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="8"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Large Intestine Perforation</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Pelvic Abscess</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Peritonitis</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Post Procedural Bile Leak</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Small Intestinal Perforation</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Small Intestine Gangrene</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="1"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Different Mode of Usage of Doripenem</title>
        <time_frame>5 to 14 days</time_frame>
        <safety_issue>No</safety_issue>
        <population>Intent-to-treat (ITT) population: Included all enrolled participants who received at least one dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Nosocomial Pneumonia (NP)</title>
            <description>500 mg of doripenem was administered every 8 hours as 1 or 4-hour infusion for 7 to 14 days</description>
          </group>
          <group group_id="O2">
            <title>Ventilator-Associated Pneumonia (VAP)</title>
            <description>500 mg of doripenem was administered every 8 hours as 1 or 4-hour infusion for 7 to 14 days</description>
          </group>
          <group group_id="O3">
            <title>Complicated Urinary Tract Infection (cUTI)</title>
            <description>500 mg of doripenem was administered every 8 hours as 1-hour infusion for 5 to 14 days</description>
          </group>
          <group group_id="O4">
            <title>Complicated Intra-abdominal Infection (cIAI)</title>
            <description>500 mg of doripenem was administered every 8 hours as 1-hour infusion for 10 days</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="53"/>
                  <measurement group_id="O2" value="77"/>
                  <measurement group_id="O3" value="19"/>
                  <measurement group_id="O4" value="67"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Participants With Different Mode of Usage of Doripenem</title>
            <units>Participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Monotherapy</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="41"/>
                  <measurement group_id="O2" value="66"/>
                  <measurement group_id="O3" value="18"/>
                  <measurement group_id="O4" value="62"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Combination Therapy</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="12"/>
                  <measurement group_id="O2" value="11"/>
                  <measurement group_id="O3" value="1"/>
                  <measurement group_id="O4" value="5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>First Line Therapy</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="16"/>
                  <measurement group_id="O2" value="33"/>
                  <measurement group_id="O3" value="3"/>
                  <measurement group_id="O4" value="30"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Second Line Therapy</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="37"/>
                  <measurement group_id="O2" value="44"/>
                  <measurement group_id="O3" value="16"/>
                  <measurement group_id="O4" value="37"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Duration of Antibiotic Therapy</title>
        <description>Duration of doripenem and duration of doripenem plus oral antibiotics therapy</description>
        <time_frame>5 to 14 days</time_frame>
        <safety_issue>No</safety_issue>
        <population>Intent-to-treat (ITT) population: Included all enrolled participants who received at least one dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Nosocomial Pneumonia (NP)</title>
            <description>500 mg of doripenem was administered every 8 hours as 1 or 4-hour infusion for 7 to 14 days</description>
          </group>
          <group group_id="O2">
            <title>Ventilator-Associated Pneumonia (VAP)</title>
            <description>500 mg of doripenem was administered every 8 hours as 1 or 4-hour infusion for 7 to 14 days</description>
          </group>
          <group group_id="O3">
            <title>Complicated Urinary Tract Infection (cUTI)</title>
            <description>500 mg of doripenem was administered every 8 hours as 1-hour infusion for 5 to 14 days</description>
          </group>
          <group group_id="O4">
            <title>Complicated Intra-abdominal Infection (cIAI)</title>
            <description>500 mg of doripenem was administered every 8 hours as 1-hour infusion for 10 days</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="53"/>
                  <measurement group_id="O2" value="77"/>
                  <measurement group_id="O3" value="19"/>
                  <measurement group_id="O4" value="67"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Duration of Antibiotic Therapy</title>
            <description>Duration of doripenem and duration of doripenem plus oral antibiotics therapy</description>
            <units>Days</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>Duration of doripenem therapy</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7.4" spread="3.51"/>
                  <measurement group_id="O2" value="9.2" spread="4.67"/>
                  <measurement group_id="O3" value="6.9" spread="2.46"/>
                  <measurement group_id="O4" value="6.9" spread="2.86"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Duration of doripenem plus oral antibiotic therapy</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7.5" spread="3.57"/>
                  <measurement group_id="O2" value="9.9" spread="6.07"/>
                  <measurement group_id="O3" value="9.1" spread="3.94"/>
                  <measurement group_id="O4" value="8.3" spread="4.50"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Acute Physiology and Chronic Health Evaluation II (APACHE II) Score</title>
        <description>APACHE II is a severity of disease classification system and the score will be determined in the participants admitted to the Intensive Care Unit upon study enrollment to help predict the risk of mortality for critically ill patients. It consists of, A: acute physiology score (APS; range, 0 to 4), B: age points (range, 0 [less than or equal to 44] to 6 [greater than or equal to 75]) and C: chronic health points (2 [elective postoperative patient] and 5 [non-operative or emergency postoperative patient]). Total APACHE II score is sum of A, B and C.</description>
        <time_frame>Baseline (Day -1)</time_frame>
        <safety_issue>No</safety_issue>
        <population>Intent-to-treat (ITT) population: Included all enrolled participants who received at least one dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Nosocomial Pneumonia (NP)</title>
            <description>500 mg of doripenem was administered every 8 hours as 1 or 4-hour infusion for 7 to 14 days</description>
          </group>
          <group group_id="O2">
            <title>Ventilator-Associated Pneumonia (VAP)</title>
            <description>500 mg of doripenem was administered every 8 hours as 1 or 4-hour infusion for 7 to 14 days</description>
          </group>
          <group group_id="O3">
            <title>Complicated Urinary Tract Infection (cUTI)</title>
            <description>500 mg of doripenem was administered every 8 hours as 1-hour infusion for 5 to 14 days</description>
          </group>
          <group group_id="O4">
            <title>Complicated Intra-abdominal Infection (cIAI)</title>
            <description>500 mg of doripenem was administered every 8 hours as 1-hour infusion for 10 days</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="53"/>
                  <measurement group_id="O2" value="77"/>
                  <measurement group_id="O3" value="19"/>
                  <measurement group_id="O4" value="67"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Participants With Acute Physiology and Chronic Health Evaluation II (APACHE II) Score</title>
            <description>APACHE II is a severity of disease classification system and the score will be determined in the participants admitted to the Intensive Care Unit upon study enrollment to help predict the risk of mortality for critically ill patients. It consists of, A: acute physiology score (APS; range, 0 to 4), B: age points (range, 0 [less than or equal to 44] to 6 [greater than or equal to 75]) and C: chronic health points (2 [elective postoperative patient] and 5 [non-operative or emergency postoperative patient]). Total APACHE II score is sum of A, B and C.</description>
            <units>Participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>APACHE II score: less than or equal to 14</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="34"/>
                  <measurement group_id="O2" value="50"/>
                  <measurement group_id="O3" value="11"/>
                  <measurement group_id="O4" value="58"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>APACHE II score: 15 to 19</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="8"/>
                  <measurement group_id="O2" value="15"/>
                  <measurement group_id="O3" value="3"/>
                  <measurement group_id="O4" value="6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>APACHE II score: 20 to 24</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4"/>
                  <measurement group_id="O2" value="7"/>
                  <measurement group_id="O3" value="1"/>
                  <measurement group_id="O4" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>APACHE II score: 25 to 29</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="4"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>APACHE II score: greater than or equal to 30</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Missing</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="4"/>
                  <measurement group_id="O4" value="1"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Achieved Clinical Cure, Clinical Failure and Intermediate Outcome at End-of-treatment Visit (EOT)</title>
        <time_frame>Day 5 or Day 7 or Day 14</time_frame>
        <safety_issue>No</safety_issue>
        <population>Intent-to-treat (ITT) population: Included all enrolled participants who received at least one dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Nosocomial Pneumonia (NP)</title>
            <description>500 mg of doripenem was administered every 8 hours as 1 or 4-hour infusion for 7 to 14 days</description>
          </group>
          <group group_id="O2">
            <title>Ventilator-Associated Pneumonia (VAP)</title>
            <description>500 mg of doripenem was administered every 8 hours as 1 or 4-hour infusion for 7 to 14 days</description>
          </group>
          <group group_id="O3">
            <title>Complicated Urinary Tract Infection (cUTI)</title>
            <description>500 mg of doripenem was administered every 8 hours as 1-hour infusion for 5 to 14 days</description>
          </group>
          <group group_id="O4">
            <title>Complicated Intra-abdominal Infection (cIAI)</title>
            <description>500 mg of doripenem was administered every 8 hours as 1-hour infusion for 10 days</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="53"/>
                  <measurement group_id="O2" value="77"/>
                  <measurement group_id="O3" value="19"/>
                  <measurement group_id="O4" value="67"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Participants Who Achieved Clinical Cure, Clinical Failure and Intermediate Outcome at End-of-treatment Visit (EOT)</title>
            <units>Participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Clinical cure</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="33"/>
                  <measurement group_id="O2" value="49"/>
                  <measurement group_id="O3" value="15"/>
                  <measurement group_id="O4" value="46"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Clinical failure</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7"/>
                  <measurement group_id="O2" value="7"/>
                  <measurement group_id="O3" value="2"/>
                  <measurement group_id="O4" value="6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Indeterminate outcome</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5"/>
                  <measurement group_id="O2" value="15"/>
                  <measurement group_id="O3" value="1"/>
                  <measurement group_id="O4" value="10"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Missing data</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="8"/>
                  <measurement group_id="O2" value="6"/>
                  <measurement group_id="O3" value="1"/>
                  <measurement group_id="O4" value="5"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Achieved Clinical Cure, or Experienced Clinical Failure, Relapse or Intermediate Outcome at Test-of-cure (TOC) Visit</title>
        <time_frame>End-of-treatment (Day 5 or Day 7 or Day 14) plus 7 to 14 days</time_frame>
        <safety_issue>No</safety_issue>
        <population>Intent-to-treat (ITT) population: Included all enrolled participants who received at least one dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Nosocomial Pneumonia (NP)</title>
            <description>500 mg of doripenem was administered every 8 hours as 1 or 4-hour infusion for 7 to 14 days</description>
          </group>
          <group group_id="O2">
            <title>Ventilator-Associated Pneumonia (VAP)</title>
            <description>500 mg of doripenem was administered every 8 hours as 1 or 4-hour infusion for 7 to 14 days</description>
          </group>
          <group group_id="O3">
            <title>Complicated Urinary Tract Infection (cUTI)</title>
            <description>500 mg of doripenem was administered every 8 hours as 1-hour infusion for 5 to 14 days</description>
          </group>
          <group group_id="O4">
            <title>Complicated Intra-abdominal Infection (cIAI)</title>
            <description>500 mg of doripenem was administered every 8 hours as 1-hour infusion for 10 days</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="53"/>
                  <measurement group_id="O2" value="77"/>
                  <measurement group_id="O3" value="19"/>
                  <measurement group_id="O4" value="67"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Participants Who Achieved Clinical Cure, or Experienced Clinical Failure, Relapse or Intermediate Outcome at Test-of-cure (TOC) Visit</title>
            <units>Participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Clinical cure</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="25"/>
                  <measurement group_id="O2" value="39"/>
                  <measurement group_id="O3" value="12"/>
                  <measurement group_id="O4" value="46"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Clinical failure</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="5"/>
                  <measurement group_id="O3" value="2"/>
                  <measurement group_id="O4" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Relapse</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="5"/>
                  <measurement group_id="O3" value="1"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Indeterminate outcome</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4"/>
                  <measurement group_id="O2" value="8"/>
                  <measurement group_id="O3" value="1"/>
                  <measurement group_id="O4" value="4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Missing data</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="22"/>
                  <measurement group_id="O2" value="20"/>
                  <measurement group_id="O3" value="3"/>
                  <measurement group_id="O4" value="14"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Experienced Eradication, Presumed Eradication, Persistence, Presumed Persistence and Indeterminate Response at End-of-treatment Visit (EOT) Visit</title>
        <time_frame>Day 5 or Day 7 or Day 14</time_frame>
        <safety_issue>No</safety_issue>
        <population>Microbiological Modified Intent-to-Treat Population (mMITT): included participants who had a baseline pathogen identified, regardless of susceptibility to study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Nosocomial Pneumonia (NP)</title>
            <description>500 mg of doripenem was administered every 8 hours as 1 or 4-hour infusion for 7 to 14 days</description>
          </group>
          <group group_id="O2">
            <title>Ventilator-Associated Pneumonia (VAP)</title>
            <description>500 mg of doripenem was administered every 8 hours as 1 or 4-hour infusion for 7 to 14 days</description>
          </group>
          <group group_id="O3">
            <title>Complicated Urinary Tract Infection (cUTI)</title>
            <description>500 mg of doripenem was administered every 8 hours as 1-hour infusion for 5 to 14 days</description>
          </group>
          <group group_id="O4">
            <title>Complicated Intra-abdominal Infection (cIAI)</title>
            <description>500 mg of doripenem was administered every 8 hours as 1-hour infusion for 10 days</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="26"/>
                  <measurement group_id="O2" value="63"/>
                  <measurement group_id="O3" value="10"/>
                  <measurement group_id="O4" value="42"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Participants Who Experienced Eradication, Presumed Eradication, Persistence, Presumed Persistence and Indeterminate Response at End-of-treatment Visit (EOT) Visit</title>
            <units>Participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Eradication</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7"/>
                  <measurement group_id="O2" value="12"/>
                  <measurement group_id="O3" value="3"/>
                  <measurement group_id="O4" value="7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Presumed eradication</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="10"/>
                  <measurement group_id="O2" value="18"/>
                  <measurement group_id="O3" value="4"/>
                  <measurement group_id="O4" value="18"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Persistence</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="14"/>
                  <measurement group_id="O3" value="1"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Presumed persistence</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                  <measurement group_id="O2" value="4"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Indeterminate</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                  <measurement group_id="O2" value="10"/>
                  <measurement group_id="O3" value="2"/>
                  <measurement group_id="O4" value="9"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Missing data</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                  <measurement group_id="O2" value="5"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="5"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Medical Resource Utilization</title>
        <description>Medical resource utilization included length of hospital stay, length of intensive care unit (ICU) stay, duration of mechanical ventilation and time to discharge.</description>
        <time_frame>From Baseline (Day -1) upto the duration of hospital stay of a participant</time_frame>
        <safety_issue>No</safety_issue>
        <population>Intent-to-treat (ITT) population: Included all enrolled participants who received at least one dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Nosocomial Pneumonia (NP)</title>
            <description>500 mg of doripenem was administered every 8 hours as 1 or 4-hour infusion for 7 to 14 days</description>
          </group>
          <group group_id="O2">
            <title>Ventilator-Associated Pneumonia (VAP)</title>
            <description>500 mg of doripenem was administered every 8 hours as 1 or 4-hour infusion for 7 to 14 days</description>
          </group>
          <group group_id="O3">
            <title>Complicated Urinary Tract Infection (cUTI)</title>
            <description>500 mg of doripenem was administered every 8 hours as 1-hour infusion for 5 to 14 days</description>
          </group>
          <group group_id="O4">
            <title>Complicated Intra-abdominal Infection (cIAI)</title>
            <description>500 mg of doripenem was administered every 8 hours as 1-hour infusion for 10 days</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="53"/>
                  <measurement group_id="O2" value="77"/>
                  <measurement group_id="O3" value="19"/>
                  <measurement group_id="O4" value="67"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Medical Resource Utilization</title>
            <description>Medical resource utilization included length of hospital stay, length of intensive care unit (ICU) stay, duration of mechanical ventilation and time to discharge.</description>
            <units>Days</units>
            <param>Median</param>
            <dispersion>Full Range</dispersion>
            <category_list>
              <category>
                <sub_title>Length of hospital stay</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="21" spread="25.89" lower_limit="3" upper_limit="138"/>
                  <measurement group_id="O2" value="33" spread="26.95" lower_limit="5" upper_limit="132"/>
                  <measurement group_id="O3" value="13" spread="12.19" lower_limit="7" upper_limit="53"/>
                  <measurement group_id="O4" value="12" spread="17.60" lower_limit="5" upper_limit="80"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Length of Intensive Care Unit (ICU) Stay</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="8" spread="14.40" lower_limit="2" upper_limit="54"/>
                  <measurement group_id="O2" value="17" spread="16.34" lower_limit="3" upper_limit="66"/>
                  <measurement group_id="O3" value="4" spread="9.76" lower_limit="2" upper_limit="27"/>
                  <measurement group_id="O4" value="7" spread="10.21" lower_limit="1" upper_limit="52"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Duration of Mechanical Ventilation</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="6" spread="11.88" lower_limit="1" upper_limit="46"/>
                  <measurement group_id="O2" value="15" spread="21.61" lower_limit="3" upper_limit="115"/>
                  <measurement group_id="O3" value="2" spread="1.92" lower_limit="1" upper_limit="6"/>
                  <measurement group_id="O4" value="4" spread="9.30" lower_limit="1" upper_limit="44"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Time to Discharge</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="13" spread="15.23" lower_limit="1" upper_limit="63"/>
                  <measurement group_id="O2" value="19" spread="18.96" lower_limit="1" upper_limit="97"/>
                  <measurement group_id="O3" value="8" spread="7.72" lower_limit="3" upper_limit="35"/>
                  <measurement group_id="O4" value="9" spread="16.42" lower_limit="2" upper_limit="88"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Readmitted to the Intensive Care Unit (ICU) Within 28 Days After End-of-treatment (EOT)</title>
        <time_frame>Within 28 days after EOT (Day 5 or Day 7 or Day 14)</time_frame>
        <safety_issue>No</safety_issue>
        <population>Intent-to-treat (ITT) population: Included all enrolled participants who received at least one dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Nosocomial Pneumonia (NP)</title>
            <description>500 mg of doripenem was administered every 8 hours as 1 or 4-hour infusion for 7 to 14 days</description>
          </group>
          <group group_id="O2">
            <title>Ventilator-Associated Pneumonia (VAP)</title>
            <description>500 mg of doripenem was administered every 8 hours as 1 or 4-hour infusion for 7 to 14 days</description>
          </group>
          <group group_id="O3">
            <title>Complicated Urinary Tract Infection (cUTI)</title>
            <description>500 mg of doripenem was administered every 8 hours as 1-hour infusion for 5 to 14 days</description>
          </group>
          <group group_id="O4">
            <title>Complicated Intra-abdominal Infection (cIAI)</title>
            <description>500 mg of doripenem was administered every 8 hours as 1-hour infusion for 10 days</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="8"/>
                  <measurement group_id="O2" value="19"/>
                  <measurement group_id="O3" value="1"/>
                  <measurement group_id="O4" value="6"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Participants Readmitted to the Intensive Care Unit (ICU) Within 28 Days After End-of-treatment (EOT)</title>
            <units>Participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Participant still in hospital</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="8"/>
                  <measurement group_id="O2" value="19"/>
                  <measurement group_id="O3" value="1"/>
                  <measurement group_id="O4" value="6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Participant readmitted in ICU</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Readmitted to the Hospital Within 28 Days After End-of-treatment (EOT)</title>
        <time_frame>Within 28 days after EOT (Day 5 or Day 7 or Day 14)</time_frame>
        <safety_issue>No</safety_issue>
        <population>Intent-to-treat (ITT) population: Included all enrolled participants who received at least one dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Nosocomial Pneumonia (NP)</title>
            <description>500 mg of doripenem was administered every 8 hours as 1 or 4-hour infusion for 7 to 14 days</description>
          </group>
          <group group_id="O2">
            <title>Ventilator-Associated Pneumonia (VAP)</title>
            <description>500 mg of doripenem was administered every 8 hours as 1 or 4-hour infusion for 7 to 14 days</description>
          </group>
          <group group_id="O3">
            <title>Complicated Urinary Tract Infection (cUTI)</title>
            <description>500 mg of doripenem was administered every 8 hours as 1-hour infusion for 5 to 14 days</description>
          </group>
          <group group_id="O4">
            <title>Complicated Intra-abdominal Infection (cIAI)</title>
            <description>500 mg of doripenem was administered every 8 hours as 1-hour infusion for 10 days</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="30"/>
                  <measurement group_id="O2" value="44"/>
                  <measurement group_id="O3" value="18"/>
                  <measurement group_id="O4" value="54"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Participants Readmitted to the Hospital Within 28 Days After End-of-treatment (EOT)</title>
            <units>Participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Participants discharged from hospital</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="30"/>
                  <measurement group_id="O2" value="44"/>
                  <measurement group_id="O3" value="18"/>
                  <measurement group_id="O4" value="54"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Participants readmitted to hospital</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="4"/>
                  <measurement group_id="O3" value="1"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From the time a signed and dated informed consent form is obtained until 30 days after the last dose of study medicaton.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Nosocomial Pneumonia (NP)</title>
          <description>500 mg of doripenem was administered every 8 hours as 1 or 4-hour infusion for 7 to 14 days</description>
        </group>
        <group group_id="E2">
          <title>Ventilator-Associated Pneumonia (VAP)</title>
          <description>500 mg of doripenem was administered every 8 hours as 1 or 4-hour infusion for 7 to 14 days</description>
        </group>
        <group group_id="E3">
          <title>Complicated Urinary Tract Infection (cUTI)</title>
          <description>500 mg of doripenem was administered every 8 hours as 1-hour infusion for 5 to 14 days</description>
        </group>
        <group group_id="E4">
          <title>Complicated Intra-abdominal Infection (cIAI)</title>
          <description>500 mg of doripenem was administered every 8 hours as 1-hour infusion for 10 days</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA Version 14.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="19"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Disseminated Intravascular Coagulation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Coronary Syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Acute Myocardial Infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="77"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Atrial Fibrillation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="77"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Cardiac Arrest</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Cardiac Failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Cardio-Respiratory Arrest</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Cardiogenic Shock</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Mitral Valve Stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Right Ventricular Failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastric Ulcer Perforation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Gastrointestinal Perforation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Melaena</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Multi-Organ Failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abdominal Wall Abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Brain Abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="53"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="77"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="53"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="77"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Septic Shock</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="53"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="77"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Wound Infection Fungal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Endotracheal Intubation Complication</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Head Injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Operative Haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Procedural Hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Tracheostomy Malfunction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Traumatic Brain Injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood Creatinine Increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Oxygen Saturation Decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="77"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="53"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Post-Traumatic Amnestic Disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Anuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="77"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Renal Failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Renal Failure Acute</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="53"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dependence On Respirator</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Haemothorax</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Laryngeal Oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Pleural Effusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Pneumonia Aspiration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Pulmonary Hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Pulmonary Oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Respiratory Distress</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="53"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Respiratory Failure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="53"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="77"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Decubitus Ulcer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Subcutaneous Emphysema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Haemodynamic Instability</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA Version 14.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="19"/>
                <counts group_id="E4" subjects_affected="32" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="53"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="77"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Eosinophilia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Thrombocytosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="77"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial Fibrillation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="77"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Left Ventricular Failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Myocardial Ischaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Sinus Tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Distension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="77"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E4" events="3" subjects_affected="2" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Duodenitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Haematemesis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Haematochezia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Parotid Gland Enlargement</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Upper Gastrointestinal Haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="53"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Acinetobacter Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="77"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Candiduria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Herpes Dermatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Liver Abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Nosocomial Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="77"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Peritoneal Tuberculosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="77"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Postoperative Wound Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Soft Tissue Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Staphylococcal Bacteraemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="77"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Staphylococcal Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Staphylococcal Sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Stenotrophomonas Sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="53"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="77"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Wound Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine Aminotransferase Increased</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="53"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="77"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Aspartate Aminotransferase Increased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="53"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Bilirubin Conjugated Increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Blood Alkaline Phosphatase Increased</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="53"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="77"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Blood Bicarbonate Increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Blood Bilirubin Unconjugated Increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Blood Cortisol Decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Blood Creatine Phosphokinase Increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Blood Lactate Dehydrogenase Increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="77"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Blood Triglycerides Increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Coagulation Time Prolonged</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Creatinine Renal Clearance Decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Gamma-Glutamyltransferase Abnormal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Gamma-Glutamyltransferase Increased</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="53"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Glomerular Filtration Rate Decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Haematocrit Increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Haemoglobin Increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Hepatic Enzyme Increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Liver Function Test Abnormal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Oxygen Saturation Decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Red Blood Cell Count Decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Transaminases Increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>White Blood Cell Count Decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>White Blood Cell Count Increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes Mellitus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Fluid Overload</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Hypercalcaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="77"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Hypernatraemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Hypertriglyceridaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Hypoalbuminaemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="53"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Hypochloraemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="53"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="77"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Hypoproteinaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Metabolic Alkalosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Decubitus Ulcer</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="53"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="77"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Pruritus Generalised</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Subcutaneous Emphysema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Phlebitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="53"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" events="6" subjects_affected="4" subjects_at_risk="19"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Withdrawal Hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>VP MEDICAL AFFAIRS ASIA PACIFIC</name_or_title>
      <organization>Jan-Cil Singapore</organization>
      <phone>+65 6827 6753</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>
